" class="no-js "lang="en-US"> The Native Antigen Company Strengthens Senior Team to Support Growing Product Portfolio - Medtech Alert
Saturday, May 18, 2024

The Native Antigen Company Strengthens Senior Team to Support Growing Product Portfolio

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, has announced two key appointments to its management team. Richard White has joined the Company as Business Development Manager, and Pardeep Sharda as Senior Product Manager. The appointments follow the Native Antigen Company’s recent move to new state-of-the-art facilities at the Oxford Technology Park and form part of its strategy to further expand its extensive product portfolio, with over 30 new products in the pipeline.

Richard will be responsible for growing the Company’s presence in the North American market and ensuring both customers and the business are supported as the Company continues to expand. Richard brings with him over 20 years’ diverse commercial experience in multiple functions including sales, marketing, and diagnostics. His expertise includes developing and executing tactical business strategies to enhance efficiency and branding for diagnostics. As Senior Product Manager, Pardeep will focus on building and developing marketing strategies both for the Company’s existing product range and assisting in the design of innovative new products. Pardeep has extensive experience in driving marketing strategies, with his most recent roles including Senior Global Product Manager at QIAGEN, and Marketing Manager at Roche.

Strengthening the Native Antigen Company’s management team will facilitate its drive to scale-up manufacturing of infectious disease reagents, antibodies and assays as part of the Company’s transition to the brand-new facility, opened by LGC Clinical Diagnostics at the Oxford Technology Park. The 36,000 square foot facility was officially opened in October by the creators of the Oxford AstraZeneca COVID-19 vaccine, Dame Sarah Gilbert DBE and Teresa Lambe OBE, and will host the manufacturing facilities for The Native Antigen Company alongside an advanced workflow applications laboratory for LGC Biosearch Technologies.

Ish Jalal, Commercial Director, The Native Antigen Company, said: “These appointments mark a major milestone for us as we continue to grow the Company both in terms of size and of our product offerings. Coupled with the news of our brand new, cutting-edge facilities opening in Oxford, the expansion of our senior team makes for a very exciting time for The Native Antigen Company.”

Richard White, Business Development Manager, The Native Antigen Company, commented: “I’m looking forward to working with the team at The Native Antigen Company, continuing on the growth trajectory that the Company has already seen over the past few years. With the Company’s recent move to new facilities, we have greatly increased our capacity, giving exciting opportunities for new business, as well as enabling us to continue to anticipate and support our existing customers needs.”

Pardeep Sharda, Senior Product Manager, The Native Antigen Company, added: “This is a fantastic time to be joining the team, as we enter the next stage of the Company’s development. With LGC’s backing, there is huge scope for further product development and expansion of our core capabilities, which I am looking forward to being a part of.”

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more